Lenalidomide Accord

Lenalidomide, the active ingredient in Lenalidomide Accord, is an immunomodulatory drug presented as an oral formulation for systemic use. It is indicated for the treatment of multiple myeloma and certain myelodysplastic syndromes in adult patients.

GNH USA supplies Lenalidomide Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is used in hematologic malignancies and related bone‑marrow disorders.

Multiple Myeloma: improves disease control and prolongs survival in patients with relapsed or refractory disease. Myelodysplastic Syndromes: reduces transfusion dependence and delays progression to acute leukemia in selected high‑risk patients.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: reduced neutrophil count, increasing infection risk. - Thrombocytopenia: low platelet levels, leading to easy bruising. - Diarrhea: loose stools that may be mild to moderate. - Constipation: difficulty passing stool. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: markedly low neutrophils requiring medical intervention. - Severe thrombocytopenia: dangerous drop in platelets. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: liver enzyme elevations or injury. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating Lenalidomide, several safety considerations should be addressed.

Dose adjustment: assess renal function and modify dose accordingly. Pregnancy risk: contraindicated in pregnancy; enforce effective contraception for both patient and partner. Infection monitoring: watch for signs of infection and treat promptly. Thromboembolism prophylaxis: consider anticoagulation in patients with additional risk factors. Hematologic monitoring: perform regular complete blood counts to detect cytopenias. Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Lenalidomide can interact with other medicines, affecting its safety or efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide exposure and toxicity. - Anticoagulants (e.g., warfarin): may heighten bleeding risk.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inducers (e.g., rifampin): may reduce lenalidomide plasma levels. - Immunosuppressants (e.g., cyclosporine): may amplify immunosuppressive effects. - Live vaccines: increased risk of infection due to immune modulation.